Sliptin M 500 MG


Sliptin M 500 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Sitagliptin + Metformin Hydrochloride



This is often demonstrated as an aide to count calories and work out to make strides glycemic control in grown-ups with sort 2 diabetes mellitus when treatment with both sitagliptin and metformin is suitableImperative confinements of use:
  • This ought to not be utilized in patients with sort 1 diabetes or for the treatment of diabetic ketoacidosis, because it would not be efective in these settings.
  • This has not been considered in patients with a history of pancreatitis. It is obscure whether patients with a history of pancreatitis are at expanded chance for the advancement of pancreatitis whereas utilizing This.



This tablet combines two antihyperglycemic operators with complementary components of activity to progress glycemic control in patients with sort 2 diabetes. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin HCl, a part of the biguanide lesson. Sitagliptin may be a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is accepted to apply its activities in patients with sort 2 diabetes by abating the inactivation of incretin hormones. Incretin hormones, counting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are discharged by the digestive system all through the day, and levels are expanded in reaction to a dinner. These hormones are quickly inactivated by the protein, DPP-4. The incretins are part of an endogenous framework included within the physiologic control of glucose homeostasis.When blood glucose concentrations are ordinary or lifted at that point GLP-1 and GIP increment affront amalgamation and discharge from pancreatic beta cells by intracellular signaling pathways including cyclic AMP. GLP-1 too brings down glucagon discharge from pancreatic alpha cells, driving to diminished hepatic glucose generation. By expanding and dragging out dynamic incretin levels, Sitagliptin increments affront discharge and diminishes glucagon levels within the circulation in a glucose-dependent way. The pharmacologic component of activity of Metformin HCl is distinctive from other classes of verbal antihyperglycemic operators. Metformin HCl diminishes hepatic glucose generationdiminishes intestinal assimilation of glucose and increments fringe glucose take-up and utilization.


Dosage & Administration

Dosage of film-coated tablet: The measurement of this tablet ought to be individualized on the premise of the patient’s current regimen, efectiveness, and tolerability whereas not surpassing the greatest suggested day by day dosage of 100 mg sitagliptin and 2000 mg metformin. Starting combination treatment or upkeep of combination treatment ought to be individualized and cleared out to the watchfulness of the wellbeing care provider.

This tablet ought to for the most part be given twice every day with dinners, with progressive dosage acceleration, to diminish the gastrointestinal (GI) side efects due to metformin.

The beginning dosage of this tablet ought to be based on the patient’s current regimen. This tablet ought to be given twice every day with meals.

The prescribed beginning dosage in patients not right now treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice day by day, with continuous measurements acceleration prescribed to decrease gastrointestinal side efects related with metformin.

The beginning dosage in patients as of now treated with metformin ought to give sitagliptin dosed as 50 mg twice day by day (100 mg add up to day by day dosage) and the dosage of metformin as of now being taken. For patients taking metformin 850 mg twice day by day, the suggested beginning measurements of this tablet is 50 mg sitagliptin/1000 mg metformin hydrochloride twice every day.
No thinks about have been performed specifcally looking at the security and efcacy of Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP in patients already treated with other verbal antihyperglycemic operators and exchanged to Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP. Any alter in treatment of sort 2 diabetes ought to be attempted with care and fitting checking as changes in glycemic control can happen.
Dosage of extended-release tablet: Regulate once every day with a supper ideally within the evening. Steadily heighten the dosage to decrease the gastrointestinal side impacts due to Metformin. May alter the dosing based on adequacy and tolerability whereas not surpassing the most extreme prescribed day by day measurements of 100 mg Sitagliptin and 2000 mg Metformin extended-release. Keep up the same add up to day by day measurements of Sitagliptin and Metformin when changing between film-coated tablet and extended-release tablet, without surpassing the most extreme prescribed every day dosage of 2000 mg Metformin extended-release.
Patients utilizing two extended-release tablets (such as two 50/500 or two 50/1000 tablets) ought to take the two tablets together once every day. The 100 mg Sitagliptin/1000 mg Metformin HCI extended-release tablet ought to be taken as a single tablet once daily.

Patients treated with an affront secretagogue or affront: Co-administration of the combination with an affront secretagogue (e.g., sulfonylurea) or affront may require lower measurements of the affront secretagogue or affront to diminish the hazard of hypoglycemia.


Cationic Drugs: Cationic drugs dispensed with by renal tubular dischargeUtilize with caution.

Phenprocoumon: Metformin may diminish the anticoagulant impact of phenprocoumon. Hencenear checking of the INR is recommended.
Levothyroxine: Levothyroxine can decrease the hypoglycemic impact of metformin. Observing of blood glucose levels is prescribedparticularly when thyroid hormone treatment is started or ceased, and the measurement of metformin must be balanced in the event that essential.



This tablet is contraindicated in patients with:

  • Renal infection or renal brokenness, e.g., as proposed by serum creatinine levels ≥1.5 mg/dL [guys], ≥1.4 mg/dL [females] or unusual creatinine clearance which may moreover result from conditions such as cardiovascular collapse (stun), intense myocardial localized necrosis, and septicemia
  • Acute or incessant metabolic acidosis, counting diabetic ketoacidosis, with or without coma.
  • History of a genuine touchiness response to this tablet or sitagliptin, such as anaphylaxis or angioedema.
This tablet ought to be briefly ceased in patients experiencing radiologic ponders including intravascular organization of iodinated differentiate materials, since utilize of such items may result in intense modification of renal work.


Side Effects

The foremost common antagonistic responses detailed in ≥5% of patients at the same time begun on sitagliptin and metformin and more commonly than in patients treated with fake treatment were loose bowels, upper respiratory tract contamination, and headache.

 Adverse responses detailed in ≥5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with fake treatment in combination with sulfonylurea and metformin were hypoglycemia and migraine.
Hypoglycemia was the as it were antagonistic response detailed in ≥5% of patients treated with sitagliptin in combination with affront and metformin and more commonly than in patients treated with fake treatment in combination with affront and metformin.

Nasopharyngitis was the as it were antagonistic response detailed in ≥5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.
The most common (>5%) unfavorable responses due to start of metformin treatment are the runs, nausea/vomiting, fatulence, stomach inconvenienceacid reflux, asthenia, and migraine.


Pregnancy & Lactation

Pregnancy Category B. There are no satisfactory and well-controlled thinks about in pregnant ladies with Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP or its person components; subsequently, the security of Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP in pregnant ladies isn’t known. This tablet ought to be utilized amid pregnancy as it were if clearly needed.

It isn’t known whether sitagliptin is excreted in human drainSince numerous drugs are excreted in human drain, caution ought to be worked out when this tablet is managed to a nursing lady.

Precautions & Warnings

Lactic Acidosis-

  • Lactic acidosis can happen due to metformin collection. The chance increments with conditions such as sepsis, drying outabundance liquor admissions, hepatic insufciency, renal disability, and intense congestive heart failure.
  • Symptoms incorporate discomfort, myalgias, respiratory troubleexpanding drowsiness, and nonspecifc stomach troubleResearch facility anomalies incorporate moo pH, expanded anion crevice and raised blood lactate.
  • If acidosis is suspected, suspend this tablet and hospitalize the persistent instantly.
  • Normal checking of thyroid-stimulating hormone (TSH) levels is suggested in patients with hypothyroidism.
  • Long-term treatment with metformin has been related with a diminish in vitamin B12 serum levels which may cause fringe neuropathy. Checking of the vitamin B12 level is suggested.

  • Do not utilize this tablet in patients with hepatic disease. There have been postmarketing reports of intense renal disappointmentnow and then requiring dialysis. Some time recently starting this tablet and at slightest yearly from there onevaluate renal work and confirm as normal.
  • There have been postmarketing reports of intense pancreatitis, counting lethal and non-fatal hemorrhagic or necrotizing pancreatitis. On the off chance that pancreatitis is suspected, instantly suspend this tablet.
  • Measure hematologic parameters yearly.
  • Caution patients against intemperate liquor intake.
  • May got to suspend this tablet and briefly utilize affront amid periods of push and diminished admissions of liquids and nourishment as may happen with fever, injurydisease or surgery.
  • Promptly assess patients already controlled on this tablet who create research facility anomalies or clinical ailment for prove of ketoacidosis or lactic acidosis.
  • When utilized with an affront secretagogue (e.g., sulfonylurea) or with affront, a lower dosage of the affront secretagogue or affront may be required to diminish the hazard of hypoglycemia.
  • There have been postmarketing reports of genuine unfavorably susceptible and touchiness responses in patients treated with sitagliptin (one of the components of this tablet ), such as anaphylaxis, angioedema, and exfoliative skin conditions counting Stevens-Johnson disorder. In such cases, instantly halt this tablet, survey for other potential causes, and established suitable observing and treatment, and start elective treatment for diabetes.
  • There have been no clinical considers building up conclusive prove of macrovascular hazard lessening with Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP or any other anti-diabetic sedate.

Therapeutic Class

Combination Oral hypoglycemic arrangements


Storage Conditions

Store underneath 25°C in a dry put absent from light. Keep the drugs in a secure put, out of the reach of children. Don’t utilize afterward than the date of expiry. To be apportioned as it were on the medicine of a enlisted doctor.


Pharmaceutical Name

Drug International Ltd.